

ABBRACCHIO, M.P., CERUTI, S., BRAMBILLA, D., CAMURRI, A., FRANCESCHI, C., GIAMMARIOLI, A.M., JACOBSON, K.A., CATTABENI, F. & MALORNI, W. (1998). Adenosine A₃ receptors and viability of astrocytes. *Drug. Dev. Res.*, **45**, 379-386.

ABBRACCHIO, M.P., CAMURRI, A., CERUTI, S., CATTABENI, F., FALZANO, L., GIAMMARIOLI, A.M., JACOBSON, K.A., TRINCAVELLI, L., MARTNI, C., MALORNI, W. & FIORENTINI, C. (2001). The A₃ adenosine receptor induces cytoskeleton rearrangement in human astrocytoma cells via a specific action on Rho proteins. *Ann. N. Y. Acad. Sci.*, **939**, 63-73.

ALSENE, K., DECKERT, J., SAND, P. & DE WIT H. (2003). Association between A_{2A} receptor gene polymorphisms and caffeine induced anxiety. *Neuropsychopharmacol.*, **2**, 1694-1702.

ANGULO, E., CASADO, V., MALLOL, J., CANELA, E.I., VINALS, F., FERRER, I., LLUIS, C. & FRANCO R. (2003). A₁ adenosine receptors accumulate in neurodegenerative structures in Alzheimer disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation. *Brain. Pathol.*, **13**, 440-451.

AQEL, R.A., ZOGHBI, G.J. & TRIMM, J.R. (2004). Effect of caffeine administered intravenously on intracoronary-administered adenosine-induced coronary hemodynamics in patients with coronary artery disease. *Am. J. Cardiol.*, **93**, 434-446.

BARONE, J.J. & ROBERTS, H.R., (1996). Caffeine consumption. *Food Chem. Toxicol.*, **34**, 119-129.

BCHIR, F., DOGUI, M., BEN FRADJ, R., ARNAUD, M.J. & SAGUEM, S. (2006). Differences in pharmacokinetic and electroencephalographic responses to caffeine in sleep-sensitive and non-sensitive subjects. *C. R. Biol.*, **329**, 512-519.

BELARDINELLI, L., SHRYOCK, J.C., RUBLE, J., MONOPOLI, A., DIONISOTTI, S., ONGINI, E., DENNIS, D.M. & BAKER, S.P. (1996). Binding of the novel non-xantine A_{2A} adenosine receptor antagonist [³H]- SCH 58261 to coronary artery membranes. *Circ. Res.*, **79**, 1153-1160.

BIAGGIONI, I., PAUL, S., PUCKETT, A. & ARZUBIAGA, C. (1991). Caffeine and theophylline as adenosine receptor antagonists in humans. *J. Pharmacol. Exp. Ther.*, **258**, 588-593.

BOROS, I., LENGYEL, Z., BALKAY, L., HORVATH, G., SZENTMIKLOSI, A.J., FEKETE, I. & MARIAN, T. (2002). In vivo investigation of the A_{2A} adenosine receptor distribution using the [¹¹C]-CSC radioligand. *Orv. Hetil.*, **26**, 1317-1319.

BRADFORD, M.M. (1976). A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye-binding. *Anal. Biochem.*, **72**, 248.

BROUSSAS, M., CORNILLET-LEFEBVRE, P., POTRON, G. & NGUYEN, P. (2002). Adenosine inhibits tissue factor expression by LPS-stimulated human monocytes: involvement of the A₃ adenosine receptor. *Thromb. Haemost.*, **88**, 123-130.

BRUNS, R.F., (1991). Role of adenosine in energy supply/demand balance. *Nucleosides & Nucleotides*, **10**, 931.

BUNRNSTOCK, G. (2006). Purinergic signalling - an overview. *Novartis Found. Symp.*, **276**, 26-48.

BUTLER, J.J., MADERS, J.S., WATSON, C.L., ZHANG, H., BLAY, J. & HOSKIN D.W. (2003). Adenosine inhibits activation-induced T cell expression of CD2 and CD28 co-stimulatory molecules: role of interleukin-2 and cyclic AMP signalling pathways. *J. Cell. Biochem.*, **89**, 975-991.

CHANG, K.C., LIN, Y.C., CHEN, J.Y., CHOU, H.T. & HUNG, J.S. (2002). Interactions of esmolol and adenosine in atrioventricular nodal-dependent supraventricular tachycardia: implication for the cellular mechanisms of adenosine. *Cardiology*, **97**, 138-46.

CHEN, Y.H., YAO, W.Z., DING, Y.L., GENG, B., LU, M. & TANG, C.S. (2006). Effect of theophylline on endogenous hydrogen sulfide production in patients with COPD. *Pulm. Pharmacol. Ther.*

CHERN, Y., KING, K., LAI, H.L. & LAI, H.T. (1992). Molecular cloning of a novel adenosine receptor gene from rat brain. *Biochem. Biophys. Res. Commun.*, **185**, 304-309.

CRONSTEIN, B.N., DAGUMA, L., NICHOLS, D., HUTCHISON, A.J. & WILLIAMS, M. (1990) The adenosine/neutrophil paradox resolved: human neutrophils possess both A₁ and A₂ receptors that promote chemotaxis and inhibit O₂ generation, respectively. *J. Clin. Invest.*, **85**, 1150-1157

CRONSTEIN, B.N. (1994) Adenosine, an endogenous anti-inflammatory agent. *J. Appl. Physiol.*, **76**, 5-13.

CRONSTEIN, B.N., MONTESINOS, M.C. & WEISSMANN, G. (1999). Sites of action for future therapy: an adenosine dependent mechanism by which aspirin retains

its antiinflammatory activity in cyclooxygenase-2 and NFkappa knockout mice. *Osteoarthritis Cartilage*, **7**, 361-363.

CRONSTEIN, B.N. (2004). Therapeutic cocktails for rheumatoid arthritis: the mixmaster's guide. *Arthritis Rheum.*, **50**, 2041-2043.

CRONSTEIN, B.N. (2005). Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. *Pharmacol Rev.*, **57**, 163-172.

CRONSTEIN, B.N. (2006). Pharmacogenetics in the rheumatic diseases. *Bull NYU Hosp. Jt. Dis.*, **64**, 16-19.

DAL CANTO, R.A., SHAW, M.K., NOLAN, G.P., STEINMAN, L. & FATHMAN, C.G. (1999). Local delivery of TNF by retrovirus-transduced T lymphocytes exacerbates experimental autoimmune encephalomyelitis. *Clin. Immunol.*, **90**, 10-14.

DALL'IGNA, O.P., SOUZA, D.O. & LARA, D.R. (2004). Caffeine as a neuroprotective adenosine receptor antagonist. *Ann. Pharmacother.*, **38**, 717-718.

DALL'IGNA, O.P., FETT, P., GOMES, M.W., SOUZA, D.O., CUNHA, R.A. & LARA, D.R. (2007). Caffeine and adenosine A_{2A} receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice. *Exp. Neurol.*, **203**, 241-245.

DEBRY, G. (1994). *Coffee and Health*, ed. Debry, g., 1-538, John Libbey, Paris.

DELANEY, S.M. & GEIGER, J.D. (1998). Levels of endogenous adenosine in rat striatum. II. Regulation of basal and N-methyl-D-aspartate-induced levels by inhibitors of adenosine transport and metabolism. *J. Pharmacol. Exp. Ther.*, **285**, 568-572.

DHALLA, A.K., SHRYOCK, J.C., SHREENIWAS, R. & BELARDINELLI, L. (2003). Pharmacology and therapeutic applications of A₁ adenosine receptor ligands. *Curr. Top. Med. Chem.*, **3**, 369-85.

DONG, Q., GINSBERG, H.N. & ERLANGER, B.F. (2001). Overexpression of the A₁ adenosine receptor in adipose tissue protects mice from obesity-related insulin resistance. *Diabetes Obes. Metab.*, **3**, 360-366.

DUNWIDDIE, T.V., DIAO, L. & PROCTOR, W.R. (1997). Adenine nucleotides undergo rapid, quantitative conversion to adenosine in the extracellular space in rat hippocampus. *J. Neurosci.*, **17**, 7673-7682.

ELLENBOGEN, K.A., O'NEILL, G., PRYSTOWSKY, E.N., CAMM, J.A., MENG, L., LIEU, H.D., JERLING, M., SHREENIWAS, R., BELARDINELLI, L. & WOLFF, A.A.; TEMPEST Study Group (2005). Trial to evaluate the management of paroxysmal supraventricular tachycardia during an electrophysiology study with tecadenoson. *Circulation.*, **21**, 3202-3208.

ERDMANN, A.A., GAO, Z.G., JUNG, U., FOLEY, J., BORENSTEIN, T., JACOBSON, K.A. & FOWLER D.H. (2005). Activation of Th1 and Tc1 cell adenosine A_{2A} receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. *Blood.*, **15**, 4707-4714.

ETHEIR, M.F., CHANDER, V. & DOBSON, J.G. Jr. (1993). Adenosine stimulates proliferation of human endothelial cells in culture. *Am. J. Physiol.*, **265**, 131-138.

ETHEIR, M.F. & DOBSON, J.G. Jr. (1997). Adenosine stimulation of DNA synthesis in human endothelial cells. *Am. J. Physiol.*, **272**, 1470-1479.

EZEAMUZIE, C.I. & PHILIPS, E. (1999). Adenosine A₃ receptors on human eosinophils mediate inhibition of degranulation and superoxide anion release. *Br. J. Pharmacol.*, **127**, 188-194.

FAN, M. & MUSTAFA, S.J. (2006). Role of adenosine in airway inflammation in an allergic mouse model of asthma. *Int. Immunopharmacol.*, **6**, 36-45.

FELDMAN, M., BRENNAN, F.M. & MAINI, R.N. (1996). Role of cytokines in rheumatoid arthritis. *Annu. Rev. Immunol.*, **5**, 195-202.

FEOKTISTOV, I. & BIAGGIONI, I. (1997). Adenosine A_{2B} receptors; a novel therapeutic target in asthma? *Pharmacol. Rev.*, **19**, 148-153.

FEOKTISTOV, I., POLOSA, R., HOLGATE, S.T. & BIAGGIONI, I. (1998). Adenosine A_{2B} receptors: a novel therapeutic target in asthma. *Trends Pharmacol. Sci.*, **49**, 148-153.

FERRE, S., POPOLI, P., GIMENEZ,-LLORT, L., RIMONDINI, R., MULLER, C.E., STROMBERG, I., OGREN, S.O. & FUXE, K. (). Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease. *Parkinsonism Relat. Disord.*, **7**, 235-241.

FINK, J.S., WEAVER, A.R., RIVKEES, S.A., PETERFREUND, R.A., POLLACK, A.E., ADLER, E.M. & REPERT, S.M. (1992). Molecular cloning of rat A₂ adenosine receptor: selective coexpression with D₂ dopamine receptors in rat striatum. *Brain Res. Mol. Brain Res.*, **14**, 186-195.

FISHMAN, P., BAR-YEHUDA, S., FARBSTEIN, T., BARER, F. & OHANA, G. (2000). Adenosine acts as a chemoprotective agent by stimulating G-CSF: a role for A₁ and A₃ adenosine receptor. *J. Cell. Physiol.*, **183**, 393-398.

FISHMAN, P., BAR-YEHUDA, S., MADI, L. & COHN, I. (2002). A₃ adenosine receptor as a target for cancer therapy. *Anticancer Drugs.*, **13**, 437-43.

FORMAN, M.B., STONE, G.W. & JACKSON, E.K. (2006). Role of adenosine as adjunctive therapy in acute myocardial infarction. *Cardiovasc. Drug Rev.*, **24**, 116-147.

FORTIN, A., HARBOUR, D., FERNANDES, M., BORGEAT, P. & BOURGOIN, S. (2006). Differential expression of adenosine receptors in human neutrophils: up-regulation by specific Th1 cytokines and lipopolysaccharide. *J. Leukoc. Biol.*, **79**, 574-85.

FOSSETTA, J., JACKSON, J., DENO, G., FAN, X., DU, X.K., BOBER, L., SOUDE-BERMEJO, A., DE BOUTEILLER, O., CAUX, C., LUNN, C., LUNDELL, D. & PALMER, R.K. (2003). Pharmacological analysis of calcium responses mediated by the human A₃ adenosine receptor in monocyte-derived dendritic cells and recombinant cells. *Mol. Pharmacol.*, **63**, 342-350.

FRARY, C.D., JOHNSON, R.K. & WANG M.Q. (2005). Food sources and intakes of caffeine in the diets of persons in the United States. *J. Am. Diet. Assoc.*, **105**, 110-113.

FREDHOLM, B.B., BATTIG, K., HOLMEN, J., NEHLIG, A. & ZVARTAU, E.E. (1999). Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. *Pharmacol. Rev.*, **51**, 83-133.

FREDHOLM, B.B., ARSLAN, G., HALLDNER, L., KULL, B., SCHULTE, G. & WASSERMAN, W. (2000). Structure and function of adenosine receptors and their genes. *Naunyn Schmiedeberg's Arch. Pharmacol.*, **362**, 364-74.

FREDHOLM, B.B., IJZERMAN, A.P., JACOBSON, K.A., KLOTZ, K.N. & LINDEN, J. (2001a). International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. *Pharmacol Rev.*, **53**, 527-552.

FREDHOLM, B.B., IRENIUS, E., KULL, B. & SCHULTE, G. (2001b). Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. *Biochem. Pharmacol.*, **61**, 443-448.

FREDHOLM, B.B. (2003a). Adenosine receptors as targets for drug development. *Drug. News Perspect.*, **16**, 283-9.

FREDHOLM, B.B., CUNHA, R.A. & SVENNINGSSON, P. (2003b). Pharmacology of adenosine A_{2A} receptors and therapeutic applications. *Curr. Top Med. Chem.*, **3**, 413-426.

FREDHOLM, B.B. (2004). Connection between caffeine, adenosine receptors and dopamine. Coffee reduces the risk of Parkinson disease. *Lakartidningen.*, **101**, 2552-2555.

FREISSMUTH, M., SCHUTZ, W. LINDER, M.E. (1991). Interactions of the bovine brain A₁-adenosine receptor with recombinant G-protein α -subunits. Selectivity for rG_{1 α -3}. *J. Biol. Chem.*, **266**, 17778-17783.

FURLONG, T.J., PIERCE, K.D., SELBIE, L.A. & SHINE, J. (1992). Molecular characterization of a human brain adenosine A₂ receptor. *Brain Res. Mol. Brain Res.*, **15**, 62-66.

FUXE, K., STROMBERG, I., POPOLI, P., RIMONDINI-GIORGINI, R., TORVINEN, M., OGREN, S.O., FRANCO, R., AGNATI, L.F. & FERRE, S. (2001). Adenosine receptors and Parkinson's disease. Relevance of antagonistic

adenosine and dopamine receptor interactions in the striatum. *Adv. Neurol.*, **86**, 345-53.

GARDNER, N.M. & BROADLEY, K.J. (1999). Analysis of the atypical characteristics of adenosine receptors mediating negative inotropic and chronotropic responses of guinea-pig isolated atria and papillary muscles. *Br. J. Pharmacol.*, **127**, 1619-26.

GESSI, S., VARANI, K., MERIGHI, S., ONGINI, E. & BOREA, P.A. (2000). A_{2A} adenosine receptors in human peripheral blood cells. *Br. J. Pharmacol.*, **129**, 2-11.

GESSI, S., VARANI, K., MERIGHI, S., MORELLI, A., FERRARI, D., LEUNG, E., BARALDI, P.G., SPALLUTO, P., BOREA, P.A. (2001). Pharmacological and biochemical characterization of A₃ adenosine receptors in Jurkat T cells. *British Journal of Pharmacology*, **134**, 116-126.

GESSI, S., VARANI, K., MERIGHI, S., CATTABRIGA, E., IANNOTTA, V., LEUNG, E., BARALDI, P.G. & BOREA, P.A. (2002). A₃ adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study. *Mol. Pharmacol.*, **61**, 415-424.

GESSI, S., VARANI, K., MERIGHI, S., CATTABRIGA, E., AVITABILE, A., GAVIOLI, R., FORTINI, C., LEUNG E., MAC LENNAN, S. & BOREA, P.A. (2004a). Expression of A₃ adenosine receptors in human lymphocytes: up-regulation in T cell activation. *Mol. Pharmacol.*, **65**, 711-719.

GESSI, S., CATTABRIGA, E., AVITABILE, A., GAFA', R., LANZA, G., CAVAZZINI, L., BIANCHI, N., GAMBARI, R., FEO, C., LIBONI, A., GULLINI, S., LEUNG, E., MAC LENNAN, S. & BOREA, P.A. (2004b). Elevated expression of A₃ adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. *Clin. Cancer Res.*, **10**, 5895-5901.

GESSI, S., MERIGHI, S., VARANI, K., CATTABRIGA, E., BENINI, A., MIRANDOLA, P., LEUNG, E., MAC LENNAN, S., FEO, C., BARALDI, S. & BOREA, P.A. (2004c). Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: Focus on the A₃ adenosine subtype. *J. Cell. Physiol.*, **211**, 826-836.

GESSI, S., VARANI, K., MERIGHI, S., CATTABRIGA, E., AVITABILE, A., GAVIOLI, R., LEUNG, E., MAC LENNAN, S. & BOREA P.A. (2004d). Expression of A₃ adenosine receptors in human lymphocytes: up-regulation in T-cell activation. *Mol. Pharmacol.*, **65**, 711-719.

GESSI, S., VARANI, K., MERIGHI, S., CATTABRIGA, E., PANCALDI, C., SZABADKAI, Y., RIZZUTO, R., KLOTZ, K.N., LEUNG, E., MAC LENNAN, S., BARALDI, P.G. & BOREA, P.A. (2005). Expression, pharmacological profile and functional coupling of A_{2B} receptors in a recombinant system and in peripheral blood cells by using a novel selective antagonist radioligand, [³H]- MRE 2029F20. *Mol. Pharmacol.*, **67**, 1-11.

GOMEZ, G. & SITKOVSKY, M.V. (2003). Targeting G protein-coupled A_{2A} adenosine receptors to engineer inflammation in vivo. *J. Biochem. Cell. Biol.*, **35**, 410-414.

GORMAN, M.W., OGIMOTO, K., SAVAGE, M.V., JACOBSON, K.A. & FEIGL E.O. (2003). Nucleotide coronary vasodilation in guinea pig hearts. *Am. J. Physiol. Heart Circ. Physiol.*, **285**, 1040-1047.

GOTTLIEB, S.S. (2001). Renal effects of adenosine A₁-receptor antagonists in congestive heart failure. *Drugs*, **61**, 1387-93.

GRAHAM, T.E. (2001). Caffeine and exercise: metabolism, endurance and performance. *Sports Med.*, **31**, 785-807.

GRIFFITHS, R.R. & MUMFORD, G.K. (1995). Caffeine: a drug of abuse? *Psychopharmacology: The Fourt Generation of Progress*, ed. Bloom, F.E., Kupfer, D.J., 1699-1713, Raven Press, New York.

HALLDNER, L., ADEN, U., DAHLBERG, V., JOHANSSON, B., LEDENT, C. & FREDHOLM, B.B. (2004). The adenosine A₁ receptor contributes to the stimulatory, but not the inhibitory effect of caffeine on locomotion: a study in mice lacking adenosine A₁ and/or A_{2A} receptors. *Neuropharmacology*, **46**, 1008-1017.

HAYNES, J. Jr., OBIK, B., BABAL, P.& STEVENS, T. (1999). 5-(N-ethylcarboxamido) adenosine desensitizes the A_{2B} adenosine receptor in lung circulation. *Am. J. Physiol.*, **276**, 1877-1883.

HIGDON, J.V. & FREI, B. (2006). Coffee and health: a review of recent human research. *Crit. Rev. Food Sci. Nutr.*, **46**, 101-123.

HIGUCHI, R., FOCKLER, C., DOLLINGER, G. & WATSON, R. (1993). Kinetic PCR analysis: real-time monitoring of DNA amplification reactions. *Biotechnology*, **11**, 26-1030.

HINSCHEN, A.K., ROSEMEYER, R.B. & HEADRICK, J.P. (2003). Adenosine receptor subtypes mediating coronary vasodilation in rat hearts. *J. Cardiovasc. Pharmacol.*, **41**, 73-80.

HORRIGAN, L.A., KELLY, J.P. & CONNOR, T.J. (2004). Caffeine suppresses TNF- α production via activation of the cyclic AMP/protein kinase A pathway. *Intern. Immunopharm.*, **4**, 1409-1417.

HUANG, Z.L., QU, W.M., EGUCHI, N., CHEN, J.F., SCHWARTZSCHILD, M.A., FREDHOLM, B.B., URADE, Y. & HAYAISHI, O. (2005). Adenosine A_{2A}, but not A₁, receptors mediate the arousal effect of caffeine. *Nat. Neurosci.*, **8**, 858-859.

HUTCHISON, K.A., NERVIS, B., PERINI, F. & FOCS, I.H. (1990). Soluble and membrane-associated human low affinity adenosine binding protein (adenosine): properties and homology with mammalian and avian stress proteins. *Biochemistry*, **29**, 5138-5144.

IJZERMAN, A.P., VON FRIJTAG DRABBE KUNZEL, J.K., KIM, J., JIANG, Q. & JACOBSON, K.A. (1996). Site-directed mutagenesis of the human adenosine A_{2A} receptor. Critical involvement of Glu13 in agonist recognition. *Eur. J. Pharmacol.*, **310**, 269-272.

JACOBSON, K.A., STILES, G.L. & JI, X.D. (1992). Chemical modification and irreversible inhibition of striatal A_{2A} adenosine receptors. *Mol. Pharmacol.*, **42**, 123-133.

JACOBSON, K.A., GALLO-RODRIGUEZ, C., MELAN, N., FICHER, B., MAILLARD, M., VAN BERGEN, A., VAN GALEN, P.J.M. & KARTON, Y. (1993). Structure-activity relationship of 8-styrylxanthines as A₂ selective adenosine antagonists. *J. Med. Chem.*, **36**, 1333-1342.

JACOBSON, M.A., JOHNSON, R.G., LUNEAU, C.J. & SALVATORE, C.A. (1995). Cloning and chromosomal localization of the human A_{2B} adenosine receptor gene (ADORA2B) and its pseudogene. *Genomics*, **27**, 374-376.

JAFARI, M. & RABBANI, A. (2000). Dose and time dependent effects of caffeine on superoxide release, cell survival and DNA fragmentation of alveolar macrophages from rat lung. *Toxicology*, **149**, 101-108.

JAFARI, M. & RABBANI, A. (2004). Studies on the mechanism of caffeine action in alveolar macrophages: caffeine elevates cyclic adenosine monophosphate level and prostaglandin synthesis. *Metabolism*, **253**, 687-692.

JENNER, T.L. & ROSEMEYER, R.B. (2006). Adenosine A₃ receptor mediated coronary vasodilation in the rat heart: changes that occur with maturation. *Mech. Ageing. Dev.*, **127**, 264-273.

JI, X., KIM, Y.C., AHERN, D.G., LINDEN, J. & JACOBSON, K.A. (2001). [³H] MRS 1754, a selective antagonist radioligand for A_{2B} adenosine receptors. *Biochem. Pharmacol.*, **61**, 657-663.

JOHANSSOM, B., GEORGIEV, V., LINDSTROM, K. & FREDHOLM, B.B. (1997). A₁ and A_{2A} adenosine receptors and mRNA in mouse brain: effect of long term caffeine treatment. *Brain. Res.*, **762**, 153-164.

KHONO, Y., JI, X., MAWHORTER, S.D., KOSHIBA, M. & JACOBSON, K.A. (1996). Activation of A₃ adenosine receptors on human eosinophils elevate intracellular calcium. *Blood*, **88**, 3568-3574.

KINSEL, J.F. & SITKOVSKY, M.V. (2003). Possible targeting of G protein coupled receptor to manipulate inflammation in vivo using synthetic and natural ligands. *Ann. Rheum. Dis.* **62**, 22-24.

KLINGER, M., FREISSMUTH, M. & NANOFF, C. (2002). Adenosine receptors: G protein-mediated signalling and the role of accessory proteins. *Cell Signaling*, **14**, 99-108.

KOLACHALA, V.L., OBERTONE, T.S., WANG, L., MERLIN, D. & SITARAMAN, S.V. (2006). Adenosine A_{2B} receptor (A_{2b}R) signals through

adenylate cyclase (AC) 6 isoform in the intestinal epithelial cells. *Biochim. Biophys. Acta.*, **1760**, 1102-1108.

KOOLPE, M., PEARSON, D. & BENTON, H.P. (1999). Expression of both P₁ and P₂ purine receptor genes by human articular chondrocytes and profile of ligand-mediated prostaglandin E₂ release. *Arthritis Rheum.*, **42**, 258-267.

KUI, X., BASTIA, E. & SCHWARZSCHILD (2005). Therapeutical potential of adenosine A_{2A} receptor antagonists in Parkinson's disease. *Pharmacol. & Therap.*, **105**, 267-310.

KUZMIN, A., JOHANSSON, B., GIMENEZ, L., OGREN, S.O. & FREDHOLM, B.B. (2006). Combination of adenosine A₁ and A_{2A} receptor blocking agents induces caffeine-like locomotor stimulation in mice. *Eur. Neuropsychopharmacol.*, **16**, 129-136.

LANDOLT, H.P., DIJK, D.J., GAUS, S.E. & BORBELY, A.A. (1995). Caffeine reduces low-frequency delta activity in the human sleep EEG. *Neuropsychopharmacology*, **12**, 229-238.

LAUDADIO, M.A. & PSARROPOULOU, C. (2004). The A₃ adenosine receptor agonist 2-Cl-IB-MECA facilitates epileptiform discharges in the CA3 area of immature rat hippocampal slices. *Epilepsy Res.*, **59**, 83-94.

LEDENT, C., VAUGEOIS, J.M., SCHIFFMAN, S.N., PEDRAZZINI, T., EL YACOUBI, M., VANDERHAEGHEN, J.J., COSTENTIN, J., HEATH, J.K., VASSART, G. & PARMENTIER, M. (1997). Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A_{2A} receptor. *Nature*, **388**, 674-678.

LEI, M., COOPER, P.J., CAMELLITI, P. & KOHL, P. (2002). Role of the 293b-sensitive, slowly activating delayed rectifier potassium current, $i(K_s)$, in pacemaker activity of rabbit isolated sino-atrial node cells. *Cardiovasc. Res.*, **53**, 68-79.

LERMAN, B.B., ELLENBOGEN, K.A., KADISH, A., PLATIA, E., STEIN, K.M., MARKOWITZ, S.M., MITTAL, S., SLOTWINER, D.J., SCHEINER, M., IWAI, S., BELARDINELLI, L., JERLING, M., SHREENIWAS, R. & WOLFF, A.A. (2001). Electrophysiologic effects of a novel selective adenosine A_1 agonist (CVT-510) on atrioventricular nodal conduction in humans. *J. Cardiovasc. Pharmacol. Ther.*, **6**, 237-45.

LIBERT, F., VAN SANDE, J., LEFFORT, A., CZERNILOFSKY, A., DUMONT, J.E., VASSART, G., ENSINGER, H.A. & MENDLA, K.D. (1992). *Biochem. Biophys. Res. Comm.*, **187**, 919.

LINDEN, J., TUCKER, A.L. & LYNCH, K.R. (1991). Molecular cloning of adenosine A_1 and A_2 receptors. *TIPS*, **12**, 326-328.

LINDEN, J. (1994). Cloned adenosine A_3 receptors: pharmacological properties, differences and receptor function. *Trend Pharmacol. Sci.*, **15**, 298-306.

LINDEN, J. (2001). Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. *Annu. Rev. Pharmacol. Toxicol.*, **41**, 775-787.

LOPES, L.V., REBOLA, N., PINHEIRO, P.C., RICHARDSON, P.J., OLIVEIRA, C.R. & CUNHA, R.A. (2003). Adenosine A_3 receptors are located in neurons of the rat hippocampus. *Neuroreport.*, **14**, 1645-1648.

LOPEZ, J.R., DOMINGUEZ-RAMIREZ, A.M., COOK, H.J., BRAVO, G., DIAZ-REVAL, M.I., DECIGA-CAMPOS, M. & LOPEZ-MUNOZ, F.J. (2006).

Enhancement of antinociception by co-administration of ibuprofen and caffeine in arthritic rats. *Eur. J. Pharmacol.*, **544**, 31-38.

MAC COLLIN, M., PETERFREUND, R., MACDONALD, M., FINK, J.S. & GUSELLA, J. (1994). Mapping of a human A_{2A} adenosine receptor (ADORA2) to chromosome 22. *Genomic*, **20**, 332-333.

MADDOCK, H.L., BROADLEY, K.J., BRIL, A. & KHANDOUDI, N. (2001). Role of endothelium in ischaemia-induced myocardial dysfunction of isolated working hearts: cardioprotection by activation of adenosine A_{2A} receptors. *J. Auton. Pharmacol.*, **21**, 263-271.

MAIA, L. & DE MENDONCA, A. (2002). Does caffeine intake protect from Alzheimer's disease? *Eur. J. Neurol.*, **9**, 377-382.

MANDEL, H.G. (2002). Update on caffeine consumption, disposition and action. *Food Chem. Toxicol.*, **40**, 1231-1234.

MARTYNYUK, A.E., SEUBERT, C.N., ZIMA, A., MOREY, T.E., BELARDINELLI, L., LIN, G., CUCCHIARA, R.F. & DENNIS, D.M. (2002a). Contribution of I(K,ADO) to the negative dromotropic effect of adenosine. *Basic. Res. Cardiol.*, **97**, 286-94.

MARTYNYUK, A.E., ZIMA, A., SEUBERT, C.N., MOREY, T.E., BELARDINELLI, L. & DENNIS, D.M. (2002b). Potentiation of the negative dromotropic effect of adenosine by rapid heart rates: possible ionic mechanism. *Basic. Res. Cardiol.*, **97**, 295-304.

MERIGHI, S., VARANI, K., GESSI, S., CATTABRIGA, E., IANNOTTA, V., ULOUGLU, C., LEUNG, E. & BOREA, P.A. (2001). Pharmacological and

biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line. *British Journal of Pharmacology*, **134**, 1215-1226.

MERIGHI, S., MIRANDOLA, P., MILANI, D., VARANI, K., GESSI, S., KLOTZ, K.N., LEUNG, E., BARALDI, P.G. & BOREA, P.A. (2002). Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. *J. Invest. Dermatol.*, **119**, 923-933.

MERIGHI, S., BENINI, A., MIRANDOLA, P., GESSI, S., VARANI, K., LEUNG, E., MAC LENNAN, S., BARALDI, P.G. & BOREA, P.A. (2005a). A₃ adenosine receptors modulate hypoxia-inducible factor-1 α expression in human A375 melanoma cells. *Neoplasia*, **7**, 894-903.

MERIGHI, S., BENINI, A., MIRANDOLA, P., GESSI, S., VARANI, K., LEUNG, E., MAC LENNAN, S. & BOREA, P.A. (2005b). A₃ adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells. *J. Biol. Chem.*, **280**, 19516-19526.

MERIGHI, S., BENINI, A., MIRANDOLA, P., GESSI, S., VARANI, K., LEUNG, E., MAC LENNANA, S., BARALDI, P.G. & BOREA, P.A. (2007a). Hypoxia inhibits paclitaxel-induced apoptosis through adenosine-mediated phosphorylation of bad in glioblastoma cells. *Mol Pharmacol.*

MERIGHI, S., BENINI, A., MIRANDOLA, P., GESSI, S., VARANI, K., SIMIONI, C., LEUNG, E., MAC LENNAN S., BARALDI, P.G. & BOREA, P.A. (2007b). Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1 α , vascular endothelial growth factor and interleukin-8 expression in hypoxic human colon cancer cells. *Mol Pharmacol.*

MONITTO, C.L., LEVITT, R.C., DISILVESTRE, D. & HOLROYD, K.J. (1995). Localization of the A₃ adenosine receptor gene (ADORA3) to human chromosome 1p. *Genomics*, **26**, 37-638.

MONTESINOS, M.C., YAP, J.S., DESAI, A., POSADAS, I., MCCRARY, C.T. & CRONSTEIN, B.N. (2000). Reversal of the anti-inflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the anti-inflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. *Arthritis. Rheum.*, **43**, 663-665.

MONTESINOS, M.C., TAKEDACHI, M., THOMPSON, L.F., WILDER, T.F., FERNANDEZ, P. & CRONSTEIN, B.N. (2007). The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5'-nucleotidase: findings in a study of ecto-5'-nucleotidase gene-deficient mice. *Arthritis Rheum.*, **56**, 1440-1445.

MORELLI, M. (2003). Adenosine A_{2A} antagonists: potential preventive and palliative treatment for Parkinson's disease. *Exp. Neurol.*, **184**, 20-23.

MORRISON, R.R., TENG, B., OLDENBURG, P.J., KATWA, L.C., SCHNERMANN, J.B. & MUSTAFA, S.J. (2006). Effects of targeted deletion of A₁ adenosine receptors on postischemic cardiac function and expression of adenosine receptor subtypes. *Am. J. Physiol. Heart Circ. Physiol.*, **291**, 1875-1882.

MUNSON, P.J. & RODBARD, D. (1980) Ligand: a versatile computerized approach for the characterization of ligand binding systems. *Anal. Biochem.*, **107**, 220-239.

MUSTAFA, S.J., NADEEM, A., FAN, M., ZHONG, H., BELARDINELLI, L. & ZENG, D. (2007). Effect of a specific and selective A_{2B} adenosine receptor

antagonist on adenosine agonist AMP and allergen-induced airway responsiveness and cellular influx in a mouse model of asthma. *J. Pharmacol. Exp. Ther.*, **320**, 1246-1251.

MYERS, M.C. (2004). Effect of caffeine on blood pressure beyond the laboratory. *Hypertension*, **43**, 724-725.

NAWROT, P., JORDAN, S., EASTWOOD, J., ROTSTEIN, J., HUGENHOLTZ, A. & FEELEY, M. (2003). Effects of caffeine on human health. *Food Addit. Contam.*, **20**, 1-30.

NOTARIUS, C.F. (2003). Caffeine and coffee tolerance. *Circulation*, **108**, 38-40.

OCHAION, A., BAR-YEHUDA, S., COHN, S., DEL VALLE, L., PEREZ-LIZ, G., MADI, L., BARER, F., FARBSTEIN, M., FISHMAN-FURMAN, S., REITBLAT, T., REITBLAT, A., AMITAL, H., LEVI, Y., MOLAD, Y., MADER, R., TISHLER, M., LANGEVITZ, P., ZABUTTI, A. & FISHMAN, P. (2006). Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A₃ adenosine receptor expression. *Arthritis Res Ther.*, **8**, 169.

OHTA, A. & SITKOVSKY, M. (2001). Role of G protein-coupled adenosine receptors in down-regulation of inflammation and protection from tissue damage. *Nature*, **414**, 916-920.

OLAH, M.E. (1997). Identification of A_{2A} adenosine receptor domains involved in selective coupling to Gs. Analysis of chimeric A₁/A_{2A} adenosine receptors. *J. Biol. Chem.*, **272**, 337-344.

ONGINI, E. & FREDHOLM, B.B. (1996). Pharmacology of adenosine A_{2A} receptors. *Trends Pharmacol. Sci.*, **17**, 364-372.

ONGINI, E. & SCHBERT, P. (1998). Neuroprotection induced by stimulating A₁ or blocking A_{2A} adenosine receptors: an apparent paradox. *Drug Dev. Res.*, **45**, 387-393.

PAGANINI-HILL, A., KAWAS, C.H. & CORRADA, M.M. (2007). Non-alcoholic beverage and caffeine consumption and mortality: The Leisure World Cohort Study. *Prev. Med.*, **44**, 305-310.

PALMER, T.M., GETTYS, T.W. & STILES, G.L. (1995). Differential interaction with and regulation of multiple G-proteins by the rat A₃ adenosine receptor. *J. Biol. Chem.*, **270**, 16895-16902.

PAUL, S., KURUNWUNE, B. & BIAGGIONI, I. (1993). Caffeine withdrawal: apparent heterologous sensitization to adenosine and prostacyclin actions in human platelets. *J. Pharmacol. Exp. Ther.*, **267**, 838-843.

PETERFREUND, R.A., MACCOLLIN, M., GUSELLA, J. & FINKN, J.S. (1996). Characterization and expression of the human A_{2A} adenosine receptor gene. *J. Neurochem.*, **66**, 362-368.

PETRIE, H.J., CHOWN, S.E., BELFIE, L.M., DUNCAN, A.M., MCLAREN, D.H. & CONQUER, J.A. (2004). Caffeine ingestion increases the insulin response to an oral-glucose-tolerance test in obese men before and after weight loss. *Am. J. Clin. Nutr.*, **80**, 22-28.

PIERSEN, C.E., TRUE, C.D. & WELLS, J.N. (1994). A carboxyl-terminally truncated mutant and non-glycosylated A_{2A} adenosine receptors retain ligand binding. *Mol. Pharmacol.*, **45**, 861-870.

PINNA, A., PONTIS, S., BORSINI, F. & MORELLI, M. (2007). Adenosine A_{2A} receptor antagonists improve deficits in initiation of movement and sensory motor

integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease. *Synapse*, **61**, 606-614.

POPOLI, P., MINGHETTI, L., TEBANO, M.T., PINTOR, A., DOMENICI, M.R. & MASSOTTI, M. (2004). Adenosine A_{2A} receptor antagonism and neuroprotection: mechanisms, lights and shadows. *Crit. Rev. Neurobiol.*, **16**, 99-106.

PORKKA-HEISKANENT, T., STRECKER, R.E., THAKKAR, M., BJORKUM, A.A., GREENE, R.W. & McCARLEY R.W. (1997). Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness. *Science*, **276**, 1265-1268.

POULSEN, S.A. & QUINN, R.J. (1998). Adenosine receptors: new opportunities for future drug. *Bioorg. & Med. Chem.*, **6**, 619-641.

PRIVIERO, F., DE NUCCI, G., ANTUNES, E. & ZANESCO, A. (2004). Negative chronotropic response to adenosine receptor stimulation in rat right atria after run training. *Clin. Exp. Pharmacol. Physiol.*, **31**, 741-743.

PRYSTOWSKY, E.N., NIAZI, I., CURTIS, A.B., WILBER, D.J., BAHNSON, T., ELLENBOGEN, K., DHALA, A., BLOOMFIELD, D.M., GOLD, M., KADISH, A., FOGEL, R.I., GONZALES, M.D., BELARDINELLI, L., SHREENIWAS, R. & WOLFF, A.A. (2003). Termination of paroxysmal supraventricular tachycardia by tecadenoson (CVT-510), a novel A₁-adenosine receptor agonist. *J. Am. Coll. Cardiol.*, **17**, 1098-1102.

RALEVIC, V. & BURNSTOCK, G. (1998). Receptors for purines and pyrimidines. *Pharmacol. Reviews*, **50**, 413-492.

REBOLA, N., PINHEIRO, P.C., OLIVEIRA, C.R., MALVA, J.O. & CUNHA, R.A. (2003). Subcellular localization of adenosine A₁ receptors in nerve terminals and synapses of the rat hippocampus. *Brain Res.*, **987**, 49-58.

REVAN, S., MONTESINOS, M.C., NAIME, D., LANDAU, S. & CRONSTEIN, B.N. (1996). Adenosine A₂ receptor occupancy regulates stimulated neutrophil function via activation of a serine/threonine protein phosphatase. *J. Biol. Chem.*, **271**, 17114-17118.

ROSS, G.W., ABBOTT, R.D., PETROVITCH, H., WHITE, L.R. & TANNER, C.M. (2000). Relationship between caffeine intake and Parkinson disease. *JAMA*, **284**, 1378-1379.

RUDOLPHI, K.A., SCHUBERT, P., PARKINSON, F.E. & FREDHOLM, B.B. (1992). Neuroprotective role of adenosine in cerebral ischaemia. *Trends. Pharmacol. Sci.*, **13**, 439-445.

SAFRAN, N., SHNEYVAYS, V., BALAS, N., JACOBSON, K.A., NAWRATH, H. & SHAINBERG, A. (2001). Cardioprotective effects of adenosine A₁ and A₃ receptor activation during hypoxia in isolated rat cardiac myocytes. *Mol. Cell. Biochem.*, **217**, 143-152.

SALVATORE, C.A., JACOBSON, M.A., TAYLOR, H.E., LINDEN, J. & JOHNSON, R.G. (1993). Molecular cloning and characterization of the human A₃ adenosine receptor. *Proc. Natl. Acad. Sci.*, **90**, 10365-10369.

SCHINDLER, C.W., KARCZ-KUBICHA, M., THORNDIKE, E.B., MULLER, C.E., TELLA, S.R., FERRE',S. & GOLDBERG, S.R. (2005). Role of central and peripheral adenosine receptors in the cardiovascular responses to intraperitoneal injections of adenosine A₁ and A_{2A} subtype receptor agonists. *Brit. J. Pharmacol.*, **144**, 642-650.

SCHRIER, S.M., VAN TILBURG, E.W., VAN DER MEULEN, H., IJZERMAN, A.P., MULDER, G.J. & NEGELKERKE, J.F. (2001). Extracellular adenosine-induced apoptosis in mouse neuroblastoma cells: studies on involvement of adenosine receptors and adenosine uptake. *Biochem. Pharmacol.*, **61**, 417-425.

SCHWABE, U., FEIN, T. & LORENZEN, A. (1993). Pharmacological properties of adenosine receptors and adenosine binding proteins. *Drug Development Research*, **28**, 220-225.

SCHWARTZ, L.M., RASCHKE, P., BECKER, B.F. & GERLACH, E. (1993) Adenosine contributes to neutrophil-mediated loss of myocardial function in postischemic guinea pig hearts. *J. Mol. Cell. Cardiol.*, **25**, 927 – 938.

SCHWARZSCHILD, M.A., AGNATI, L., FUXE, K., CHEN, J.F. & MORELLI, M. (2006). Targeting adenosine A_{2A} receptors in Parkinson's disease. *Trends Neurosci.*, **29**, 647-654.

SHI, D., NIKODIJEVIC, O., JACOBSON, K.A. & DALY, J.W. (1993). Chronic caffeine alters the density of adenosine, adrenergic, cholinergic, GABA and serotonin receptors and calcium channels in mouse brain. *Cell. Mol. Neurobiol.*, **13**, 247-261.

SHNEYVAYS, V., NAWRATH, H., JACOBSON, K.A. & SHAINBERG, A. (1998). Induction of apoptosis in cardiac myocytes by an A₃ adenosine receptor agonist. *Exp. Cell. Res.*, **243**, 383-397.

SIMOLA, N., FENU, S., BARALDI, P.G., TABRIZI, M.A. & MORELLI, M. (2006). Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease. *J. Neurol. Sci.*, **25**, 48-52.

SLIWA, K., WOODIWISS A., CANDY, G., BADENHORST, D., LIBHABER, C. & NORTON, G. (2002). Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy. *Am. J. Cardiol.*, **90**, 1118-1122.

SNELL, J. (1993). Coffee and caffeine: sleep and wakefulness. *Coffee, Caffeine and Health*, ed. Garattini, S., 255-290, Raven Press, New York.

SPICUZZA, L., DI MARIA, G. & POLOSA, R. (2006). Adenosine in the airways: implications and applications. *Eur. J. Pharmacol.*, **533**, 77-88.

SPISANI, S., GIULIANI, A.L., CAVALLETTI, T., ZACCARINI, M., MILANI, L., GAVIOLI, R. & TRANIELLO, S. (1992). Effect of cyclic AMP level reduction on human neutrophils responses to formylated peptides. *Inflammation*, **16**, 147-158.

STORR, M., THAMMER, J., DUNKEL, R., SCHUSDZIARRA, V. & ALLESCHER, H.D. (2002). Modulatory effect of adenosine receptors on the ascending and descending neural reflex responses of rat ileum. *BMC Neurosci.*, **3**, 21.

SULLIVAN, G. & LINDEN, J. (1998) Role of A_{2A} adenosine receptors in inflammation. *Drug Dev. Res.*, **45**, 103 – 112.

SUZUKI, H., TAKEI, M., NAKAHATA, T. & FUKAMACHI, H. (1998). Inhibitory effects of adenosine on degranulation of human cultured mast cells upon cross-linking of FcεRI. *Biochem. Biophys. Res. Comm.*, **242**, 97-102.

TAVANI, A., BERTUZZI, M., NEGRI, E., SORBARA, L. & LA VECCHIA, C. (2001). Alcohol, smoking, coffee and risk of non-fatal acute myocardial infarction in Italy. *Eur. J. Epidemiol.*, **17**, 1131-1137.

THIEL, M. & BARDENHEUER, H. (1992). Regulation of oxygen radical production of human polymorphonuclear leukocytes by adenosine: the role of calcium. *Pflugers Arch.*, **420**, 522-528.

THIEL, M., CALDWELL, C.C. & SITKOVSKY M.V. (2003). The critical role of adenosine A_{2A} receptors in down-regulation of inflammation and immunity in the pathogenesis of infection diseases. *Microbes. Infect.*, **5**, 515-526.

THONG, F.S.L. & GRAHAM, T.E. (2002). The putative roles of adenosine in insulin and exercise mediated regulation of glucose transport and glycogen metabolism in skeletal muscle. *Can. J. Appl. Physiol.*, **27**, 152-178.

TOWNSED-NICHOLSON A., BAKER, E., SUTHERLAND, G.R. & SCHOFIELD, P.R. (1995). Localization of the adenosine A_{2B} receptor subtype gene (ADORA2B) to chromosome 17p11.2-p12 by FISH and PCR screening of somatic cell hybrids. *Genomics*, **25**, 605-607.

TRINCAVELLI, M.L., TUSCANO, D., MARRONI, M, FALLENI, A., GREMIGNI, V., CERUTI, S., ABBRACCHIO, M.P., JACOBSON, K.A., CATTABENI, F. & MARTINI, C. (2002). A₃ adenosine receptors in human astrocytoma cells: agonist-mediated desensitization, internalization and down-regulation. *Mol. Pharmacol.*, **62**, 1373-1384.

TSUTSUI, S., SCHNERMANN, J., NOORBAKHSH, F., HENRY S., YONG, V.W. & WINSTON, B.W. (2004). A₁ adenosine receptor up-regulation and

activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. *J. Neurosciences*, **24**, 1521-1529.

VARANI, K., GESSI, S., DALPIAZ, A., BOREA, P.A. (1996). Pharmacological and biochemical characterization of purified A_{2A} adenosine receptors in human platelet membranes by [³H]-CGS 21680 binding. *British Journal of Pharmacology*, **117**, 1693-1701.

VARANI, K., GESSI, S., DALPIAZ, A. & BOREA P.A. (1997). Characterization of A_{2A} adenosine receptor in human lymphocyte membranes by [³H] SCH 58261 binding. *Br. J. Pharmacol.*, **122**, 386-392.

VARANI, K., GESSI, S., DIONISOTTI, S., ONGINI, E. & BOREA P.A. (1998a). [³H]-SCH 58261 labelling of functional A_{2A} adenosine receptors in human neutrophil membranes. *Br. J. Pharmacol.*, **123**, 1723 – 1731.

VARANI, K., GESSI, S., MERIGHI, S., ONGINI, E. & BOREA P.A. (1998b). Adenosine A_{2A} receptors of human circulating blood elements. *Drug Dev. Res.*, **45**, 253-260.

VARANI, K., PORTALUPPI, F., MERIGHI, S., ONGINI, E., BELARDINELLI, L. & BOREA, P.A. (1999). Caffeine alters A_{2A} adenosine receptors and their function in human platelets. *Circulation*, **99**, 2499-2502.

VARANI, K., PORTALUPPI, F., GESSI, S., MERIGHI, S., ONGINI, E. & BELARDINELLI, L. (2000a). Dose and time effects of caffeine intake on human platelet adenosine A_{2A} receptors. Functional and biochemical aspects. *Circulation*, **102**, 285-289.

VARANI, K., MERIGHI, S., GESSI, S., KLOTZ, K.N., LEUNG, E., BARALDI, P.G., CACCIARI, B., ROMAGNOLI, R., SPALLUTO, G. & BOREA, P.A. (2000b). [³H] MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A₃ adenosine receptors. *Molec. Pharmacol.*, **57**, 968-975.

VARANI, K., GESSI, S., MERIGHI, S., IANNOTTA, V., CATTABRIGA, E., SPISANI, S., CADOSSO, R. & BOREA, P.A. (2002). Effect of low frequency electromagnetic fields on A_{2A} adenosine receptors in human neutrophils. *Br. J. Pharmacol.*, **136**, 57-66.

VARANI, K., LAGHI-PASINI, F., CAMURRI, A., CAPECCHI, P.L., MACCHERINI, M., DICIOLLA, F., CECCATELLI, L., LAZZERINI, P.E., ULUOGLU, C., CATTABENI, F., BOREA, P.A. & ABBRACCHIO, M.P. (2003). Changes of peripheral A_{2A} adenosine receptors in chronic heart failure and cardiac transplantation. *FASEB J.*, **17**, 280-282.

VARANI, K., GESSI, S., MERIGHI, S., VINCENZI, F., CATTABRIGA, E., BENINI, A., KLOTZ, K. N., BARALDI, P.G., TABRIZI, M.A., MACLENNAN, S., LEUNG, E. & BOREA, P.A. (2005). Pharmacological characterization of novel adenosine ligands in recombinant and native human A_{2B} receptors. *Biochem. Pharmacol.*, **70**, 1601-1612.

VARANI, K., CARAMORI, G., VINCENZI, F., ADOCK, I., CASOLARI, P., LEUNG, E., MACLENNAN, S., GESSI, S., MORELLO, S., BARNES, P.J., ITO, K., CHUNG, K.F., CAVALLESCO, G., AZZENA, G., PAPI, A. & BOREA, P.A. (2006). Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.*, **15**, 398-406.

VITZTHUM, H., WEISS, B., BACHLEITNER, W., KRAMER, B.K. & KURTZ, A. (2004). Gene expression of adenosine receptors along the nephron. *Kidney Int.*, **65**, 1180-1190.

VOLPINI, R., COSTANZI, S., VITTORI, S., CRISTALLI, G. & KLOTZ, K.N. (2003). Medicinal chemistry and pharmacology of A_{2B} adenosine receptors. *Curr. Top Med. Chem.*, **3**, 427-443.

VON LUBITZ, D.K., LIN, R.C., POPIK, P., CARTER, M.F. & JACOBSON, K.A. (1994). Adenosine A₃ stimulation and cerebral ischaemia. *Eur. J. Pharmacol.*, **263**, 59-67.

WARDAS, J. (2002). Neuroprotective role of adenosine in the CNS. *Pol. J. Pharmacol.*, **54**, 313-326.

WHITE, P.J. & NGUYEN, T.T. (2002). Chronic caffeine treatment causes changes in cardiac adenosine receptor function in rats. *Pharmacology*, **65**, 129-135.

WILLELMS, L., ASHTON, K.J. & HEADRICK, J.P. (2005). Adenosine-mediated cardioprotection in the aging myocardium. *Cardiovasc. Res.*, **1**, 245-55.

YAO, Y., SEI, Y., ABBRACCHIO, M.P., JANG, J.L., KIM, Y.C. & JACOBSON, K.A. (1997). Adenosine A₃ receptor agonist protect HL-60 and U-937 cells from apoptosis induced by A₃ antagonist. *Biochem. Biophys. Res. Commun.*, **232**, 317-322.

ZABLOCKI, J., KALLA, R., PERRY, T., PALLE, V., VARKHEDKAR, V., XIAO, D., PISCOPIO, A., MAA, T., GIMBEL, A., HAO, J., CHU, N., LEUNG, K. & ZENG, D. (2005). The discovery of a selective, high affinity A_{2B} adenosine receptor antagonist for the potential treatment of asthma. *Bioorg. Med. Chem. Lett.*, **15**, 609-612.

ZATTA, A.J., MATHERNE, G.P. & HEADRICK, J.P. (2006). Adenosine receptor-mediated coronary vascular protection in post-ischemic mouse heart. *Life Sci.*, **78**, 2426-2437.

ZHOU, Q.Y., LI, C., OLAH, M.E., JOHANSON, R.A., STILES, L. & CIVELLI, O. (1992). Molecular cloning and characterization of an adenosine receptor: the A₃ adenosine receptor. *Proc. Natl. Acad. Sci.*, **89**, 7432-7436.